Adial Pharmaceuticals, Inc (ADIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADIL Stock Price Chart Interactive Chart >
ADIL Price/Volume Stats
| Current price | $0.26 | 52-week high | $3.05 |
| Prev. close | $0.26 | 52-week low | $0.24 |
| Day low | $0.25 | Volume | 101,900 |
| Day high | $0.26 | Avg. volume | 294,284 |
| 50-day MA | $0.31 | Dividend yield | N/A |
| 200-day MA | $1.04 | Market Cap | 6.72M |
Adial Pharmaceuticals, Inc (ADIL) Company Bio
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders in the United States. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.
Latest ADIL News From Around the Web
Below are the latest news stories about ADIAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ADIL as an investment opportunity.
Maxim Group Reaffirms Their Hold Rating on Adial Pharmaceuticals (ADIL)In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report). The company's shares opened today at $0.29.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks. The analyst consensus on Adial Pharmaceuticals is currently a Hold rating.See the top stocks recommended by analysts >>The company has a one-year high of $3.52 and a one-year low of $0.24. Currently, Adial Pharmaceuticals has an average volume of 166K. |
Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateAdvancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President and Chief Executive Officer CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disor |
Forget Bargain Hunting: Play 5 Stocks With Rising P/EBet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT). |
Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)Maxim Group analyst Jason McCarthy maintained a Hold rating on Adial Pharmaceuticals (ADIL - Research Report) yesterday. The company's shares opened today at $0.42.According to TipRanks, McCarthy is an analyst with an average return of -44.0% and an 8.84% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Capricor Therapeutics.Adial Pharmaceuticals has an analyst consensus of Moderate Buy.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.00 and a one-year low of $0.34. Currently, Adial Pharmaceuticals has an average volume of 737.3K. |
Adial Pharma Touts Positive Preclinical Data From Chronic Pain CandidateAdial Pharmaceuticals Inc''s (NASDAQ: ADIL ) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain. The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not … Full story available on Benzinga.com |
ADIL Price Returns
| 1-mo | -15.12% |
| 3-mo | N/A |
| 6-mo | -81.82% |
| 1-year | -90.26% |
| 3-year | -81.17% |
| 5-year | N/A |
| YTD | -90.37% |
| 2021 | 58.82% |
| 2020 | -29.46% |
| 2019 | -52.93% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...